Journal of Natural Products
Article
1
KBr) νmax 3394, 2920, 1704, 1635, 1557, 1230, 1085, 736 cm−1; H
and 13C NMR, see Tables 1 and 3; HRESIMS m/z 634.6463 [M −
H]− (calcd for C13H879Br5N2O3, 634.6457; Δ −0.6 mmu).
was extracted with EtOAc (10 mL × 3). The organic phase was
concentrated and purified by TLC on silica gel, using cyclohexane/
EtOAc (1:1), to yield 7N,12N-dimethyldehydroaspidostomide D (4a)
(0.6 mg, 60% yield).
Aspidostomide D (4): off-white, amorphous solid; [α]25 −2.68 (c
D
1
15.3, MeOH); UV (MeOH) λmax (log ε) 228 (0.83) nm; IR (film
KBr) νmax 3276, 2923, 1696, 1668, 1535, 1435, 1318, 1044, 799 cm−1;
1H and 13C NMR, see Tables 2 and 4; HRESIMS m/z 655.6496 [M −
H]− (calcd for C15H779Br5N3O2, 655.6461; Δ −3.5 mmu).
7N,12N-Dimethyldehydroaspidostomide D (4a): colorless oil; H
NMR (CDCl3, 500 MHz) δ 7.49 (d, J = 1.9 Hz, 1H, H-17), 7.40 (dd, J
= 8.7, 1.9 Hz, 1H, H-15), 7.28 (d, J = 8.7 Hz, 1H, H-14), 6.41 (s, 1H,
H-8), 3.89 (s, 3H, N-12 Me), 3.50 (s, 3H, N-7 Me); 13C NMR
(CDCl3, 125 MHz) δ 154.0 (C-6), 135.0 (C-13), 131.1 (C-18), 128.8
(C-5), 125.8 (C-15), 123.0 (C-8), 121.2 (C-17), 114.9 (C-16), 111.3
(C-14), 111.0 (C-10), 108.7 (C-2), 105.6 (C-4), 105.2 (C-11), 103.7
(C-9), 98.2 (C-3), 35.0 (N-7 Me), 32.3 (N-12 Me); APPI-MS m/z
667.6804 [M + H]+ (calcd for C17H1179Br5N3O, 667.6814; Δ −0.1
mmu).
Aspidostomide E (5): pale yellow, amorphous solid; [α]25D −78.0 (c
1.10, MeOH); UV (MeOH) λmax (log ε) 262 (19.8), 293 (15.1) nm;
IR (film KBr) νmax 3409, 2923, 1674, 1527, 1432, 1318, 1080, 669
cm−1; 1H and 13C NMR, see Tables 2 and 4; HRESIMS m/z 669.6616
[M − H]− (calcd for C16H979Br5N3O2, 669.6617; Δ 0.1 mmu)..
Aspidostomide F (6): pale yellow, amorphous solid; UV (MeOH)
λmax (log ε) 253 (14.5), 293 (11.5) nm; IR (film KBr) νmax 3284, 2912,
Preparation of Compounds 9a and 9b. To a solution of
aspidazide A (1 mg, 0.92 μmol) in dry DMSO (1 mL) was added 2
equiv of NaH, and the mixture was stirred at rt for 20 min until the
solution turned dark green. Then, a solution of CH3I (1.2 equiv) in
DMSO was added dropwise. The reaction mixture was then stirred
overnight. A few drops of MeOH were added to remove the excess
NaH; then H2O was added (5 mL), and the mixture was extracted
with EtOAc. The organic phase was concentrated and purified by TLC
on silica gel, using cyclohexane/EtOAc (1:1), after which compounds
9a and 9b were obtained in a combined 77% yield.
1
1713, 1646, 1377, 797 cm−1; H and 13C NMR, see Tables 2 and 4
HRESIMS m/z 637.6346 [M − H]− (calcd for C15H579Br5N3O,
637.6355; Δ 0.9 mmu).
Aspidostomide G (7): white, amorphous solid; UV (MeOH) λmax
(log ε) 255 (13.6), 293 (12.1) nm; IR (film KBr) νmax 3200, 2928,
1699, 1621, 1568, 1421, 1224, 1086, 677 cm−1; 1H and 13C NMR, see
Tables 2 and 4; HRESIMS m/z 579.7494 [M − H]− (calcd for
C15H1079Br4N3O2, 579.7512; Δ 1.8 mmu).
Aspidostomide H (8): white, amorphous solid; [α]25 −25.0 (c
D
1
Compound 9a: white, amorphous solid; H NMR (CD3COCD3,
0.40, MeOH); UV (MeOH) λmax (log ε) 228 (9.5) nm; IR (film KBr)
1
νmax 3733, 1643, 1546, 1394, 1116, 666 cm−1; H and 13C NMR, see
500 MHz) δ 7.83 (bs, 2H, H-11/H-15), 6.80 (s, 1H, H-8), 6.74 (s, 1H,
H-2), 3.95 (s, 3H, O-Me), 3.43 (s, 3H, N-Me); 13C NMR
(CD3COCD3, 125 MHz) δ 154.9 (C-13), 153.8 (C-6), 135.5 (C-
11/C-15), 130.1 (C-5), 127.0 (C-9), 122.5 (C-8), 120.2 (C-2), 117.1
(C-10), 109.9 (C-12/C-14), 101.5 (C-4), 95.4 (C-3), 60.4 (O-Me),
33.5 (N-Me); HRESIMS m/z 564.7407 [M − H]− (calcd for
C15H979Br4N2O2, 564.7403; Δ −0.4 mmu).
Tables 1 and 3; HRESIMS m/z 520.8315 [M − H]− (calcd for
C15H1079Br3N2O4, 520.8425; Δ 11.0 mmu).
Aspidazide A (9): yellow, amorphous solid; UV (MeOH) λmax (log
ε) 295 (12.5) nm; IR (film KBr) νmax 3433, 1646, 1541, 1207, 1052,
872, 669 cm−1; 1H and 13C NMR, see Table 5; HRESIMS m/z
1072.4232 [M − H]− (calcd for C26H979Br8N4O4, 1072.4180; Δ −0.52
mmu).
1
Compound 9b: white, amorphous solid; H NMR (CD3COCD3,
500 MHz) δ 7.85 (bs, 2H, H-11/H-15), 7.24 (s, 1H, H-4), 6.85 (s, 1H,
H-8), 3.96 (s, 3H, O-Me), 3.49 (s, 3H, N-Me); 13C NMR
(CD3COCD3, 125 MHz) δ 155.1 (C-13), 153.5 (C-6), 135.7 (C-
11/C-15), 129.9 (C-5), 127.1 (C-9), 122.1 (C-8), 117.1 (C-10), 112.3
(C-4), 109.4 (C-12/C-14), 105.9 (C-2), 100.0 (C-3), 60.4 (O-Me),
33.8 (N-Me); HRESIMS m/z 564.7404 [M − H]− (calcd for
C15H979Br4N2O2, 564.7403; Δ −0.1 mmu).
Preparation of MTPA Esters of Compound 1. To a solution of
compound 1 (1.0 mg, 1.78 μmol) in dry pyridine (300 μL) was added
(R)-MTPA-Cl (5 μL, 26.7 μmol). After 1 h at rt, the reaction mixture
was diluted with EtOAc, extracted three times with HCl, and then
washed with H2O. The organic layer was taken to dryness, and the
product was purified by TLC using cyclohexane/EtOAc (6:4) to yield
0.7 mg of the (S)-MTPA ester of 1. Treatment of 1 (1.0 mg) with (S)-
MTPA-Cl in a similar way yielded the corresponding (R)-MTPA ester
of 1 (0.6 mg).
Preparation of Compounds 9c and 9d. To a solution of
aspidazide A (1 mg, 0.92 μmol) in dry DMSO (1 mL) was added 2
equiv of NaH, and the mixture was stirred at rt for 30 min until the
solution turned dark green. The reaction was monitored by TLC and
was quenched after 30 min. A few drops of MeOH were added to
remove the excess NaH; then H2O was added, and the mixture was
extracted with EtOAc. The organic phase was concentrated and
purified by TLC on silica gel, using cyclohexane/EtOAc (4:6), after
which compounds 9c and 9d were obtained in a combined 80% yield.
1
(S)-MTPA ester of 1: white, amorphous solid; H NMR (CDCl3,
500 MHz) δ 9.48 (bs, 1H); 6.98 (d, J = 3.1 Hz, 1H); 6.93 (bt, J = 5.6
Hz, 1H); 3.87, 3.72 (dd, J = 5.6, 4.0 Hz, 2H); 7.55 (bs, 2H).
1
(R)-MTPA ester of 1: white, amorphous solid; H NMR (CDCl3,
500 MHz) δ 9.54 (bs, 1H); 7.00 (d, J = 3.5 Hz, 1H); 7.07 (bt, J = 5.8
Hz, 1H); 3.90, 3.72 (dd, J = 5.8, 4.0 Hz, 2H); 7.34 (s, 2H).
Preparation of MTPA Esters of Compound 4. To a solution of
compound 4 (1.0 mg, 1.51 μmol) in dry pyridine (300 μL) was added
(R)-MTPA-Cl (0.30 μL, 1.51 μmol). After 1 h at rt, the reaction
mixture was diluted with EtOAc, extracted three times with 10% HCl,
and then washed with H2O. The organic layer was taken to dryness,
and the product was purified by TLC using cyclohexane/EtOAc (1:1)
to yield the (S)-MTPA ester of 4 (0.7 mg). Treatment of 4 (1.0 mg)
with (S)-MTPA-Cl in a similar way yielded the corresponding (R)-
MTPA ester of 4 (0.8 mg).
1
Compound 9c: white, amorphous solid; H NMR (CD3COCD3,
500 MHz) δ 9.81 (bd, 1H, NH amide), 7.73 (s, 2H, H-11/H-15), 6.60
(d, J = 5.0 Hz, 1H, H-8), 6.72 (s, 1H, H-2), 5.64 (s, 1H, OH);
HRESIMS m/z 535.7062 [M − H]− (calcd for C13H579Br4N2O2,
564.7090; Δ 2.8 mmu).
1
Compound 9d: white, amorphous solid; H NMR (CD3COCD3,
500 MHz) δ 10.0 (bd, 1H, NH amide), 7.74 (s, 2H, H-11/H-15), 7.25
(s, 1H, H-4), 6.66 (d, J = 5.0 Hz, 1H, H-8), 5.64 (s, 1H, OH);
HRESIMS m/z 535.7066 [M − H]− (calcd for C13H579Br4N2O2,
564.7090; Δ 2.4 mmu).
1
(S)-MTPA ester of 4: white, amorphous solid; H NMR (CDCl3,
500 MHz) δ 6.78 (d, J = 4.5 Hz, 1H); 7.18 (d, J = 8.5 Hz, 1H); 7.29
(dd, J = 8.5, 2.0 Hz, 1H); 7.15 (bs, 1H), δ 8.40 (bs, 1H).
9-O-Ethylaspidostomide C (10): yellow, amorphous solid; [α]25
D
1
5.8 (c 1.00, MeOH); UV (MeOH) λmax (log ε) 257 (14.3); IR (film
KBr) νmax 3400, 3145, 2931, 1713, 1634, 1552, 1230, 1107, 736 cm−1;
1H and 13C NMR, see Tables 1 and 3; HRESIMS m/z 662.6841 [M −
H]− (calcd for C15H1279Br5N2O3, 662.6842; Δ 0.1 mmu).
Cytotoxicity Evaluation. The effects of the different compounds
on cell growth were assayed on log phase unsynchronized monolayers
of the 786-O (human clear cell renal cell carcinoma) cell line. The cells
were cultured at 37 °C in plastic flasks in RPMI medium (Gibco;
Invitrogen Corp.) in a humidified air atmosphere with 5% CO2. Serial
passages were made by treatment of confluent monolayers with 0.25%
(R)-MTPA ester of 4: white, amorphous solid; H NMR (CDCl3,
500 MHz) δ 6.57 (d, J = 4.5 Hz, 1H); 7.19 (d, J = 9.0 Hz, 1H); 7.30
(dd, J = 9.0, 1.5 Hz, 1H); 7.16 (bs, 1H), δ 8.40 (bs, 1H).
Preparation of Compound 4a. NaH (2 equiv) was added to a
solution of 4 (1 mg, 1.51 μmol) in dry DMSO (1 mL), and the
mixture was stirred at rt for 20 min until the solution turned dark
green. Then, a solution of CH3I (230 μL, 1.2 equivs) in DMSO was
added dropwise. The reaction was monitored by TLC and was
quenched after 1 h. A few drops of MeOH were added to remove the
excess sodium hydride; then H2O was added (5 mL), and the mixture
H
dx.doi.org/10.1021/np500012y | J. Nat. Prod. XXXX, XXX, XXX−XXX